Trail­ing ri­vals, As­traZeneca of­fers a hit and a miss on key car­dio study for SGLT2 di­a­betes drug Farx­i­ga

As­traZeneca had some good news for its in­vestors ear­ly Mon­day morn­ing, re­port­ing that their Phase III car­dio study of­fered some com­pelling proof of their SGLT2 di­a­betes drug’s abil­i­ty to re­duce the risk of hos­pi­tal­iza­tion for heart fail­ure and CV death. But it was a mixed pic­ture, with Farx­i­ga falling short on a pri­ma­ry end­point for ma­jor re­duc­tion in ma­jor car­diac events com­pared to a place­bo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA